Pharmaceuticals
Clarity commences COMBAT theranostic prostate cancer trial in the US
SYDNEY, June 20, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce it has commenced its64C...
2023-06-20 21:03
2017
Longbio Pharma Presented Positive Topline Phase 1 Results for LP-003 at ERS2023
SOFIA, Bulgaria, June 20, 2023 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (abbreviated as "Longbio Pharma"), a pharmaceutical company that develops medicines for the treatment of allergy, asthma, ophthalmology and other autoimmune diseases, announced the preliminary phase I data of LP-003 ...
2023-06-20 21:00
1900
Minghui Pharmaceutical Inc. Announces First Patient Dosing in Phase 1 Clinical Studies of Both the Antibody-Drug Conjugate Programs Targeting TROP-2 or B7-H3 Respectively, for Treatment of Advanced or Metastatic Solid Tumors
SHANGHAI and HANGZHOU, China and WILMINGTON, Del., June 20, 2023 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a leading clinical-stage biopharmaceutical company, announced today that the first dosing has been completed in two phase 1 clinical studies evaluating MHB036C and MHB088C. The studies a...
2023-06-20 18:30
4993
Curocell announced encouraging updates on the next-generation anti-CD19 CAR-T, Anbalcabtagene-autoleucel at International Conference on Malignant Lymphoma (ICML) 2023
* 84% ORR (32 of 38 patients) and 71% CR (27 of 38 patients) documented after 2 million cells/kg dose anbal-cel treatment to patients in relapsed/refractory large B-cell lymphoma * Durable complete response was measured-68% at 1 month, 61% at 3 months, and 60% at 6 months respectively. DAEJEO...
2023-06-20 08:01
1113
Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development
HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 19, 2023 /PRNewswire/ -- Sirnaomics Ltd.(the "Company"; stock code: 2257, together with its subsidiaries, the"Group" or "Sirnaomics"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced the adv...
2023-06-19 21:29
4071
Allgenesis Announces Encouraging Phase 1b Data Showing AG-80308 Providing Improvements in Multiple Signs and Symptoms in Dry Eye Patients
ALHAMBRA, Calif., June 19, 2023 /PRNewswire/ -- Allgenesis Biotherapeutics Inc., a clinical-stage specialty pharmaceutical company focused on developing novel ophthalmic drugs, today announced topline data from the company's Phase1b clinical trial for AG-80308, a first-in-class, formyl peptide re...
2023-06-19 16:00
1674
Mallinckrodt Announces Publication of Real-World Data on the Use of Extracorporeal Photopheresis (ECP) in Heart Transplant Patients
- Results from the largest European and first multicenter, retrospective, observational chart review study investigating the real-world use of ECP in heart transplant patients reinforce its use as a treatment for heart transplant rejection and prevention of rejection1 - DUBLIN, June 19, 2023 /PR...
2023-06-19 06:30
2686
The 'Penicillin' of Antivirals, Xafty by Hyundai Bioscience, Opened a New Era of Treating Respiratory Viral Infections with Single Drug
- Professor Heungjeong Woo of Hallym University College of Medicine, announced the result of Xafty's clinical study at Emerging Science Session of the American Society for Microbiology (ASM) Microbe 2023 - Dr. Jo White evaluated Xafty's clinical results as "The birth of Penicillin of Antivirals"...
2023-06-18 03:30
4106
The U.S. FDA Approved the Phase I/II Clinical Trial Application to Evaluate LBL-033, An Anti-MUC16/CD3 Bispecific Antibody Developed by Leads Biolabs, in Advanced Solid Tumors Including Ovarian Cancer
NANJING, China, June 16, 2023 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") today announces that the phase I/II clinical trial application for LBL-033, an anti-MUC16/CD3 bispecific antibody, for the treatment of ovarian cancer and other m...
2023-06-16 22:01
2350
Viva Biotech Announced Strategic Investors with an Investment of Approximately US$ 210 Million
HONG KONG, June 16, 2023 /PRNewswire/ -- On June 11, 2023, Viva Biotech Holdings Group (1873.HK) announced that Viva Shanghai, the primary entity for Viva Biotech's CRO business, successfully raised nearlyUS$ 150 million through the transfer of approximately 24% of its equity interest to Temasek,...
2023-06-16 14:20
5914
Everest Medicines Appoints Dr. Mike Berry as Chief Technology Officer
SHANGHAI, June 16, 2023 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on development, manufacturing and commercialization of innovative medicines and vaccines, today announced that Dr.Mike Berry has been appointed Chief Techno...
2023-06-16 07:45
2936
Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall
* Novavax has developed a protein-based monovalent XBB.1.5 COVID vaccine candidate and is manufacturing at commercial scale with the intent to be in market during the fall vaccination campaign * Novavax shared data demonstrating that its XBB.1.5 COVID vaccine candidate induces functional immu...
2023-06-16 06:05
2864
Qiming Venture Partners fosters life science, medical and healthcare talent development First healthcare catalyst program starts recruiting in Hong Kong universities
SHANGHAI and HONG KONG, June 15, 2023 /PRNewswire/ -- Qiming Venture Partners ("Qiming") today launched its first "Catalyst: Qiming Healthcare Summer Program 2023" for universities inHong Kong, fostering talent development and cross-border integration for the life science, medical and healthcare ...
2023-06-15 22:58
3580
Mabwell Announces the U.S. FDA approval of 9MW3811 for IND
SHANGHAI, June 15, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the entire value chain of the pharmaceutical industry, announced the clinical trial application of its self-developed 9MW3811 injection for idiopathic pulmonary fibrosis has been approved by ...
2023-06-15 21:00
2124
Mabwell Publishes the Preclinical Study Results on Its Nectin-4 Targeting ADC in A Well-known AACR Journal
SHANGHAI, June 15, 2023 /PRNewswire/ -- Recently, the preclinical study results of 9MW2821, the first domestically developed Nectin-4-targeting ADC by Mabwell, were published in the renowned journal "Molecular Cancer Therapeutics" under the American Association for Cancer Research (AACR). The pap...
2023-06-15 21:00
2144
China Jo-Jo Drugstores Reports Fiscal Year 2023 Financial Results
HANGZHOU, China, June 15, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced its finan...
2023-06-15 21:00
4710
Addentax Group Corp. in Advanced Talks to Acquire Partial Stake in RMB 6 Billion-Valued Recombinant Protein Drugs and Antibody Drugs Bio-pharmaceutical Company, Shanghai Bao Pharmaceutical Company Limited
SHENZHEN, China, June 15, 2023 /PRNewswire/ -- Addentax Group Corp. ("Addentax" or the "Company") (Nasdaq: ATXG), an integrated service provider focusing on garment manufacturing, logistics services, property management and subleasing, and epidemic prevention supplies, today announced that it is ...
2023-06-15 20:00
4120
FDA Approved Utidelone Injectable (UTD1) Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer
SAN FRANCISCO, June 15, 2023 /PRNewswire/ -- Biostar Pharma, Inc. (hereinafter referred to as "Biostar"), the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the discovery, development and commercialization of innovative...
2023-06-15 19:31
1859
Springer Nature to Join Seegene's OneSystem™ Business as Strategic Partner
* Seegene announces strategic partnership with Springer Nature to expand OneSystem™ Business * Seegene and Springer Nature to jointly launch global assay development project * Springer Nature expresses active support for Seegene's vision to promote participation across global scientific com...
2023-06-15 19:00
1808
Telix Briefing: Innovation in Urology to Feature Key Opinion Leaders in Prostate and Kidney Cancer
June 21, 2023, at The Yale Club, New York City Featured speakers and Key Opinion Leaders include: Dr Christian Behrenbruch, DrColin Hayward, Kevin Richardson, Dr Brian Shuch and Dr Scott Tagawa Topics include Telix's urologic pipeline, development of novel therapeutics, imaging agents and techn...
2023-06-15 19:00
1877
Week's Top Stories
Most Reposted
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 303 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 296 media titles]
2024-11-28 17:24MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 280 media titles]
2024-11-25 10:00
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
[Picked up by 275 media titles]
2024-11-29 20:33
Most Read
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
14553
SUNLU Formnext 2024 Event Highlights: From Functional Filaments to FilaDryer E2
2024-11-23 21:00
10661
Innovative technology and applications recognised with Hong Kong ICT Awards 2024
2024-11-23 02:02
8491
